A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…
McAlinden Research PartnersMay 23, 2022
The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…
McAlinden Research PartnersMay 12, 2022
Digital health continues to garner significant investor interest as startups across the industry raked in a record-breaking $29.1 billion last…
McAlinden Research PartnersJanuary 18, 2022
The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…
McAlinden Research PartnersDecember 22, 2021
US drug store chains are set to experience heightened foot traffic now that all adults are eligible for booster shots…
McAlinden Research PartnersNovember 29, 2021
Psychedelic drugs and therapies continue to show promise as a form of treatment for a wide variety of mental health disorders.…
McAlinden Research PartnersOctober 18, 2021
Drug stores could be set to boost their revenues as COVID-19 restrictions ease and vaccine booster shot plans continue to…
McAlinden Research PartnersOctober 4, 2021
